KINIKSA

Serial Number 86765893
Registration 5566176
702

Registration Progress

Application Filed
Sep 23, 2015
Under Examination
Apr 11, 2017
Approved for Publication
Aug 16, 2016
Published for Opposition
Aug 16, 2016
Registered
Sep 18, 2018

Basic Information

Serial Number
86765893
Registration Number
5566176
Filing Date
September 23, 2015
Registration Date
September 18, 2018
Published for Opposition
August 16, 2016
Drawing Code
4

Status Summary

Current Status
Active
Status Code
702
Status Date
Jan 2, 2025
Registration
Registered
Classes
005

Rights Holder

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC.

83
Address
THIRD FLOOR, 23 OLD BOND STREET
LONDON W1S 4PZ
GB

Ownership History

Kiniksa Pharmaceuticals, Ltd.

Original Applicant
03
Hamilton HM 11 BM

Kiniksa Pharmaceuticals, Ltd.

Owner at Publication
03
Hamilton HM 11 BM

Kiniksa Pharmaceuticals, Ltd.

Original Registrant
03
Hamilton HM 11 BM

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC.

New Owner After Registration #1
83
LONDON GB

Legal Representation

Attorney
Maury M. Tepper, III

USPTO Deadlines

Next Renewal Deadline
1168 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2018-09-18)
Due Date
September 18, 2028
Grace Period Ends
March 18, 2029

Application History

37 events
Date Code Type Description
Apr 11, 2025 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 2, 2025 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jan 2, 2025 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jan 2, 2025 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 2, 2024 E815 I TEAS SECTION 8 & 15 RECEIVED
Sep 18, 2023 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Sep 18, 2018 R.PR A REGISTERED-PRINCIPAL REGISTER
Aug 15, 2018 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Aug 14, 2018 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Aug 6, 2018 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Aug 6, 2018 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jul 11, 2018 IUAF S USE AMENDMENT FILED
Jul 11, 2018 EISU I TEAS STATEMENT OF USE RECEIVED
Apr 10, 2018 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 6, 2018 EX2G S SOU EXTENSION 2 GRANTED
Apr 6, 2018 EEXT I SOU TEAS EXTENSION RECEIVED
Apr 6, 2018 EXT2 S SOU EXTENSION 2 FILED
Sep 16, 2017 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 14, 2017 EX1G S SOU EXTENSION 1 GRANTED
Sep 14, 2017 EXT1 S SOU EXTENSION 1 FILED
Sep 14, 2017 EEXT I SOU TEAS EXTENSION RECEIVED
Apr 11, 2017 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 28, 2017 ETOP T EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Sep 13, 2016 ETOF T EXTENSION OF TIME TO OPPOSE RECEIVED
Aug 16, 2016 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 16, 2016 PUBO A PUBLISHED FOR OPPOSITION
Jul 27, 2016 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 14, 2016 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 8, 2016 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 8, 2016 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 8, 2016 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 12, 2016 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 12, 2016 GNRT F NON-FINAL ACTION E-MAILED
Jan 12, 2016 CNRT R NON-FINAL ACTION WRITTEN
Jan 11, 2016 DOCK D ASSIGNED TO EXAMINER
Sep 29, 2015 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 26, 2015 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
anti-inflammatories; cardiovascular pharmaceuticals; [ pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for the prevention and treatment of dermatological diseases and disorders; ] pharmaceutical preparations for the prevention and treatment of inflammatory diseases and disorders; [ pharmaceutical preparations for the prevention and treatment of pruritus; ] pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders; pharmaceutical preparations for the prevention and treatment of cardiac diseases and disorders; pharmaceutical preparations for the prevention and treatment of immune-mediated diseases and disorders; pharmaceutical preparations for the prevention and treatment of rare diseases and disorders
First Use Anywhere: Nov 15, 2017
First Use in Commerce: Nov 15, 2017

Additional Information

Translation
The wording "KINIKSA" has no meaning in a foreign language.

Classification

International Classes
005